– Acute Myeloid Leukemia (AML) is the Second Most Widespread Hematological Malignancy in Youngsters Usually Related to Poorer Prognosis In comparison with Different Pediatric Cancers –
– This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Obtained Final Month –
– Opened Enrollment for Pediatric AML Sufferers in Ongoing Part 2 Medical Trial –
– RPDD Offers Eligibility for SLS009 to Obtain a Precedence Overview Voucher (PRV) Upon Advertising Approval that may be Transferred/Bought to Different Events –
NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Firm”), a late-stage scientific biopharmaceutical firm targeted on the event of novel therapies for a broad vary of most cancers indications, immediately introduced that the U.S. Meals and Drug Administration (FDA) has granted Uncommon Pediatric Illness Designation (RPDD) to SLS009, a extremely selective CDK9 inhibitor, for the therapy of pediatric acute myeloid leukemia (AML). The FDA beforehand granted Orphan Drug and Quick Observe Designations to SLS009 for the therapy of AML.
“Receiving our second Uncommon Pediatric Illness Designation, following pediatric acute lymphoblastic leukemia final month, is one other acknowledgment of SLS009’s novel transformational therapy potential to enhance the lives of sufferers, together with kids with AML,” mentioned Angelos Stergiou, MD, ScD h.c., President and Chief Govt Officer of SELLAS. ”This designation reinforces our dedication to addressing the pressing wants of kids with AML, together with these with treatment-resistant mutations, highlighting the promise of SLS009 to supply the specialised care and help they require, particularly contemplating the restricted therapy choices for uncommon pediatric ailments. We look ahead to continued SLS009 improvement and enrolling pediatric AML sufferers in our Part 2 scientific trial.”
AML prognosis with presently out there therapies within the refractory and/or relapsed pediatric affected person inhabitants stays poor. In a consultant examine, the 5-year total survival (OS) price in relapsed pediatric AML was 33% for all sufferers, and in sufferers whose remission lasted lower than 12 months solely 15.7%. In sufferers who didn’t obtain full remission after one course of chemotherapy 5-year total survival was 0%. About 50% of kids with pediatric AML relapse. Usually, the one remedy thought of healing in relapsed and refractory sufferers is a bone marrow transplant and the first purpose of chemotherapy is to realize remission in order that pediatric sufferers will be transplanted.
Uncommon Pediatric Illness (RPD) Designation is granted by the FDA for critical or life-threatening ailments that have an effect on fewer than 200,000 folks in the US and by which the intense or life-threatening manifestations primarily have an effect on people lower than 18 years of age. If, sooner or later, a New Drug Utility (NDA) for SLS009 for the therapy of pediatric AML is authorised by the FDA, SELLAS is likely to be eligible to obtain a Precedence Overview Voucher (PRV) that could possibly be redeemed to obtain a precedence evaluation for any subsequent advertising and marketing software. PRVs could also be utilized by the sponsor or offered to a different sponsor for his or her use and have lately offered for roughly $100 million.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage scientific biopharmaceutical firm targeted on the event of novel therapeutics for a broad vary of most cancers indications. SELLAS’ different lead product candidate, GPS, is licensed from Memorial Sloan Kettering Most cancers Heart and targets the WT1 protein, which is current in an array of tumor varieties. GPS has the potential as a monotherapy and mixture with different therapies to deal with a broad spectrum of hematologic malignancies and stable tumor indications. The Firm can be creating SLS009 (previously GFH009) – doubtlessly the primary and best-in-class differentiated small molecule CDK9 inhibitor with decreased toxicity and elevated efficiency in comparison with different CDK9 inhibitors. Information means that SLS009 demonstrated a excessive response price in AML sufferers with unfavorable prognostic components together with ASXL1 mutation, generally related to poor prognosis in varied myeloid ailments. For extra data on SELLAS, please go to www.sellaslifesciences.com.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements. All statements aside from statements of historic info are “forward-looking statements,” together with these referring to future occasions. In some instances, forward-looking statements will be recognized by terminology comparable to “plan,” “count on,” “anticipate,” “could,” “would possibly,” “will,” “ought to,” “venture,” “consider,” “estimate,” “predict,” “potential,” “intend,” or “proceed” and different phrases or phrases of comparable that means. These statements embrace, with out limitation, statements associated to the GPS scientific improvement program, together with the REGAL examine and the timing of future milestones associated thereto. These forward-looking statements are primarily based on present plans, targets, estimates, expectations, and intentions, and inherently contain vital dangers and uncertainties. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of these dangers and uncertainties, which embrace, with out limitation, dangers and uncertainties with oncology product improvement and scientific success thereof, the uncertainty of regulatory approval, and different dangers and uncertainties affecting SELLAS and its improvement packages as set forth underneath the caption “Threat Elements” in SELLAS’ Annual Report on Kind 10-Ok filed on March 28, 2024 and in its different SEC filings. Different dangers and uncertainties of which SELLAS just isn’t presently conscious may additionally have an effect on SELLAS’ forward-looking statements and should trigger precise outcomes and the timing of occasions to vary materially from these anticipated. The forward-looking statements herein are made solely as of the date hereof. SELLAS undertakes no obligation to replace or complement any forward-looking statements to mirror precise outcomes, new data, future occasions, adjustments in its expectations, or different circumstances that exist after the date as of which the forward-looking statements had been made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
